Skip to main content

Abilify Cases Selected For The Second Bellwether Trial

Abilify Cases Selected For The Second Bellwether Trial

Abilify Cases Selected For The Second Bellwether Trial

Introduction

In an August 8 order, issued by U.S. District Judge M. Casey Rodgers, a group of 40 cases has been picked for the second Abilify bellwether trial over gambling risks. Both the parties are supposed to strike off 5 cases each from this pool within 14 days from the date of the order to proceed to early bellwether process.

By October 12, the plaintiffs are required to submit a completed fact sheet as well as medical, financial and gambling record authorizations. Each side should strike of additional 5 cases and reduce the pool again to 20 for a "reasonable scope" of fact discovery.

After the completion of discovery, the parties will choose 5 cases for the final trial. The court plans to do a random replacement for any case subsequently removed from the pool.

More than 1,600 Abilify lawsuits are pending in the federal court against Bristol-Myers Squibb and Otsuka Pharmaceuticals, each claiming similar allegation that Abilify makers failed to warn about the gambling effects of the drug. Abilify lawsuits were centralized in October 2016 as a part of multidistrict litigation MDL No. 2734 (In Re: Abilify Compulsive Behavior Products Liability Litigation) for coordinated pretrial proceedings in the Northern District of Florida before Judge M. Casey Rodgers.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.